News und Analysen
![Waters Establishes Flagship Innovation and Research Laboratory in Cambridge, MA](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Waters Establishes Flagship Innovation and Research Laboratory in Cambridge, MA
Waters Corporation (NYSE:WAT) announced this week at Biotech Week Boston the establishment of Immerse™ Cambridge, a new Waters' research laboratory in the heart of Cambridge’s Kendall Square
![Illumina und die heilige GRAIL: Darum ist die Aktie abgestürzt!](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Illumina und die heilige GRAIL: Darum ist die Aktie abgestürzt!
Der US-amerikanische Biotechdienstleister Illumina (WKN: 927079) hat kürzlich die vollständige Übernahme der seinerzeit selbst gegründeten Tochtergesellschaft GRAIL für 7,1 Milliarden US-Dollar
![Illumina und die heilige GRAIL: Darum ist die Aktie abgestürzt!](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Illumina und die heilige GRAIL: Darum ist die Aktie abgestürzt!
Der US-amerikanische Biotechdienstleister Illumina (WKN: 927079) hat kürzlich die vollständige Übernahme der seinerzeit selbst gegründeten Tochtergesellschaft GRAIL für 7,1 Milliarden US-Dollar
![Illumina und die heilige GRAIL: Darum ist die Aktie abgestürzt!](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Illumina und die heilige GRAIL: Darum ist die Aktie abgestürzt!
Der US-amerikanische Biotechdienstleister Illumina (WKN: 927079) hat kürzlich die vollständige Übernahme der seinerzeit selbst gegründeten Tochtergesellschaft GRAIL für 7,1 Milliarden US-Dollar
![Illumina to Acquire GRAIL to Launch New Era of Cancer Detection](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which
![Illumina to Acquire GRAIL to Launch New Era of Cancer Detection](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which
![Illumina to Acquire GRAIL to Launch New Era of Cancer Detection](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which
![ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in
![Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and
![Humana and AtlantiCare Sign Medicare Network Agreement in Southeastern New Jersey](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Humana and AtlantiCare Sign Medicare Network Agreement in Southeastern New Jersey
Leading health and well-being company Humana Inc. (NYSE: HUM) has signed an agreement with integrated healthcare system AtlantiCare that offers in-network access for Humana Medicare Advantage
![Agilent Expands Line of Innovative Flow Cytometers with the NovoCyte Penteon](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Agilent Expands Line of Innovative Flow Cytometers with the NovoCyte Penteon
Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent NovoCyte Penteon, a sensitive flow cytometer with five lasers and up to 30 fluorescence channels. The NovoCyte Penteon
![New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. These include initial data from
![Agilent Announces Cash Dividend of 18 Cents Per Share](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Agilent Announces Cash Dividend of 18 Cents Per Share
Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 18 cents per share of common stock will be paid on Oct. 28, 2020, to all shareholders of record as of the close of
![Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial
![Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic
DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today the first ever registry dedicated to tracking the outcomes of
![Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic
DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today the first ever registry dedicated to tracking the outcomes of
![Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune
![Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas
As part of a two-day virtual Investor Day, Pfizer Inc. (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on
![Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas
As part of a two-day virtual Investor Day, Pfizer Inc. (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on
![Simulations Plus Releases ADMET Predictor® Version 10.0 (APX)](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Simulations Plus Releases ADMET Predictor® Version 10.0 (APX)
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that
![GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic Neuropathy (LHON)](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic Neuropathy (LHON)
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
![Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System
Illumina (NASDAQ: ILMN) announced today that the Australian public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and track COVID-19 using
![Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System
Illumina (NASDAQ: ILMN) announced today that the Australian public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and track COVID-19 using
![Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System
Illumina (NASDAQ: ILMN) announced today that the Australian public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and track COVID-19 using
![Novus Therapeutics Announces Acquisition of Anelixis Therapeutics](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (“Anelixis”), a privately held clinical stage biotechnology company